title: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
abstract: To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day -1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202.
authors.affiliation: Hematology Department, Ospedale Santa Croce, Cuneo, Italy. gallamini.a@ospedale.cuneo.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Caterina
authors.initials: C
authors.lastname: Patti
authors.forename: Atto
authors.initials: A
authors.lastname: Billio
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Specchia
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tucci
authors.forename: Alessandro
authors.initials: A
authors.lastname: Levis
authors.forename: Annunziata
authors.initials: A
authors.lastname: Manna
authors.forename: Vicenzo
authors.initials: V
authors.lastname: Secondo
authors.forename: Luigi
authors.initials: L
authors.lastname: Rigacci
authors.forename: Antonello
authors.initials: A
authors.lastname: Pinto
authors.forename: Emilio
authors.initials: E
authors.lastname: Iannitto
authors.forename: Valerio
authors.initials: V
authors.lastname: Zoli
authors.forename: Pierfederico
authors.initials: P
authors.lastname: Torchio
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
authors.forename: Corrado
authors.initials: C
authors.lastname: Tarella
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D015703:Antigens, CD / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000074301:CD52 Antigen; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007558:Italy; D053208:Kaplan-Meier Estimate; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012955:Societies, Medical; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone